12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Taltorvic ridaforolimus regulatory update

FDA's Oncologic Drugs Advisory Committee voted 13-1 that Taltorvic ridaforolimus from Merck did not demonstrate a favorable benefit-risk profile as a maintenance therapy for metastatic soft tissue or bone sarcoma patients with...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >